NCT00387764 - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

October 31, 2012

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

pazopanib

800 mg daily dosing continously until progression

Trial Locations (58)

1007

GSK Investigational Site, Tunis

1008

GSK Investigational Site, Tunis

1878

GSK Investigational Site, Quilmes

2298

GSK Investigational Site, Waratah

3000

GSK Investigational Site, Sfax

3084

GSK Investigational Site, Heidelberg

4000

GSK Investigational Site, San Miguel de Tucumán

4054

GSK Investigational Site, Sousse

5000

GSK Investigational Site, Córdoba

6021

GSK Investigational Site, Wellington

7000

GSK Investigational Site, Hobart

8001

GSK Investigational Site, Christchurch

12808

GSK Investigational Site, Prague

51003

GSK Investigational Site, Tartu

54600

GSK Investigational Site, Lahore

61037

GSK Investigational Site, Kharkiv

74800

GSK Investigational Site, Karachi

83092

GSK Investigational Site, Donetsk

100034

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

150054

GSK Investigational Site, Yaroslavl

198255

GSK Investigational Site, Saint Petersburg

394062

GSK Investigational Site, Voronezh

420029

GSK Investigational Site, Kazan'

443066

GSK Investigational Site, Samara

454087

GSK Investigational Site, Chelyabinsk

644013

GSK Investigational Site, Omsk

7500921

GSK Investigational Site, Santiago

90610000

GSK Investigational Site, Porto Alegre

C1405CUB

GSK Investigational Site, Capital Federal

S2000KZE

GSK Investigational Site, Rosario

A-5020

GSK Investigational Site, Salzburg

A-1100

GSK Investigational Site, Vienna

30150-270

GSK Investigational Site, Belo Horizonte

254-0364

GSK Investigational Site, Viña del Mar

656 53

GSK Investigational Site, Brno

430 12

GSK Investigational Site, Chomutov

00133

GSK Investigational Site, Rome

00152

GSK Investigational Site, Rome

LV 1002

GSK Investigational Site, Riga

LT-50009

GSK Investigational Site, Kaunas

LT-08660

GSK Investigational Site, Vilnius

80-210

GSK Investigational Site, Gdansk

31-108

GSK Investigational Site, Krakow

31-115

GSK Investigational Site, Krakow

10-226

GSK Investigational Site, Olsztyn

10-228

GSK Investigational Site, Olsztyn

115 478

GSK Investigational Site, Moscow

117 837

GSK Investigational Site, Moscow

129 128

GSK Investigational Site, Moscow

833 10

GSK Investigational Site, Bratislava

110-744

GSK Investigational Site, Seoul

120-752

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Songpa-gu, Seoul

03115

GSK Investigational Site, Kyiv

CH63 4JY

GSK Investigational Site, Bebington, Wirral

BT9 7AB

GSK Investigational Site, Belfast, Northern Ireland

M20 4BX

GSK Investigational Site, Manchester